Clinical Trial Update: Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating Fosaprepitant dimeglumine with a Granisetron transdermal system to prevent chemotherapy-induced nausea and vomiting in breast cancer pa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Granisetron transdermal system (Granisetron)
• fosaprepitant dimeglumine (fosaprepitant dimeglumine)

Snippet

Sponsor: University of Southern California | Conditions: Breast Cancer, Nausea | Phase 1 | Status: TERMINATED